Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Mobocertinib by Takeda Pharmaceutical for Metastatic Biliary Tract Cancer: Likelihood of Approval
Mobocertinib is under clinical development by Takeda Pharmaceutical and currently in Phase II for Metastatic Biliary Tract Cancer. According to...
Mobocertinib by Takeda Pharmaceutical for Duodenal Cancer: Likelihood of Approval
Mobocertinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Duodenal Cancer. According to GlobalData, Phase...
Mobocertinib by Takeda Pharmaceutical for Sarcomas: Likelihood of Approval
Mobocertinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Sarcomas. According to GlobalData, Phase I...
Mobocertinib by Takeda Pharmaceutical for Pancreatic Cancer: Likelihood of Approval
Mobocertinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...
Mobocertinib by Takeda Pharmaceutical for Cervical Cancer: Likelihood of Approval
Mobocertinib is under clinical development by Takeda Pharmaceutical and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...